We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| 4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.36 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2021 to May 2024
By Kyle Morris
4D pharma PLC said Thursday that a Phase 2 trial of the Blautix drug for irritable bowel syndrome demonstrated structural changes in the gut microbiota of patients.
Blautix could provide a significant solution for millions of patients with IBS, the study's chief investigator said.
4D pharma continues to await feedback from the U.S. Food and Drug Administration regarding the results of its Phase 2 study of Blautix, it said.
Shares in the London-listed pharmaceutical company at 0926 GMT were up 2.9 pence, or 4.8%, at 64 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
December 09, 2021 04:48 ET (09:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year 4d Pharma Chart |
1 Month 4d Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
